We included 392 older adults with a median age of 84 years (IQR 79–89). Two-thirds of the patients were female. The median CCI for the whole study population was 6 (IQR 5–7), the maximum CCI being 12.
Nonspecific clinical signs or complaints (R00-R99) accounted for 36% (n = 141), and traumatic diagnoses (S00-T98) for 27% (n = 106) of all ED diagnoses. One-fifth (n = 77) of the study ED visits involved a fall. The most common ED diagnosis was Malaise and fatigue (R53) with a prevalence of 13% (Table 1).
Of all patients, 80% had polypharmacy and 30% for excessive polypharmacy. The median number of prescribed regular medications was 7 (5–10), ranging from 0 to 20. In turn, 307 (78%) patients used at least one PIM with a median of 2 (1–3) and a maximum of 7 PIMs.
Regarding study outcomes, 32 (8.2%) patients died within 90 days of the index visit, 269 (69%) patients were admitted to hospital from the ED and 165 (42%) patients had a 90-day ED revisit. Of the patients with revisits, 43% (n = 71) had at least two ED revisits.
Table 1
Characteristics of the study data (n = 392).
Variable | N (%) / median (IQR) |
Age, years, median (IQR) | 84 (79–89) |
Female, N (%) | 263 (67) |
CCI, points, median (IQR) | 6 (5–7) |
eGFR, ml/min, median (IQR) | 61 (43–79) |
Polypharmacy, N (%) | 315 (80) |
Excessive polypharmacy, N (%) | 117 (30) |
Number of regular medications, median (IQR) | 7 (5–10) |
Use of at least one PIM, N (%) | 307 (78) |
Number of PIMs, median (IQR) | 2 (1–3) |
Characteristics of the ED visits | |
Most common ED diagnoses (ICD-10) | |
• R53 Malaise and fatigue | 50 (12.8) |
• S01 Open wound of head | 22 (5.6) |
• I48 Atrial fibrillation and flutter | 18 (4.6) |
• R42 Dizziness and giddiness | 18 (4.6) |
• J18 Pneumonia | 16 (4.1) |
ED visit involving a fall, N (%) | 77 (20) |
Study outcomes | N (%) |
90-day mortality | 32 (8.2) |
Hospital admission | 269 (69) |
90-day ED revisit | 165 (42) |
Number of 90-day ED revisits of readmitted patients, median (IQR) | 0 (0–1) |
IQR = interquartile range, CCI = Charlson Comorbidity Index, eGFR = estimated glomerular filtration rate, PIM = potentially inappropriate medication, ED = emergency department, ICD-10 = International Classification of Diseases, Tenth Revision |
Logistic regression. When investigated as ordinal variables, an increase in the number of regular medications had an unadjusted OR of 0.96 (95% CI 0.87–1.06, p = 0.419) and an adjusted OR of 0.83 (95% CI 0.72–0.94, p = 0.005) for 90-day mortality. For hospital admission, the unadjusted OR was 1.05 (95% CI 0.99–1.12, p = 0.105) and the adjusted OR was 1.04 (95% CI 0.97–1.11, p = 0.263). The unadjusted OR for 90-day ED revisit was 1.09 (95% CI 1.03–1.16, p = 0.002) and the result remained statistically significant in the adjusted model [OR 1.09 (95% CI 1.03–1.16), p = 0.014].
The increasing number of PIMs had an unadjusted OR of 0.88 (95% CI 0.54–1.43, p = 0.615) for 90-day mortality. In the adjusted model, the OR was 0.74 (95% CI 0.41–1.33, p = 0.312). For hospital admission, an increase of one in the number of PIMs had an unadjusted OR of 0.92 (95% CI 0.71–1.20, p = 0.546) and an OR of 0.89 (95% CI 0.67–1.16, p = 0.379) in the adjusted model. Regarding 90-day ED revisits, the unadjusted OR was 1.08 (95% CI 0.84–1.38, p = 0.558) and the adjusted OR was 1.08 (0.84–1.40, p = 0.548) for an increase in the number of PIMs. The logistic regression results of ordinal medication-related variables and CCI on study outcomes are illustrated in a forest plot in Fig. 1.
For 90-day mortality, an increase in CCI had an unadjusted OR of 1.60 (95% CI 1.33–1.91, p < 0.001) and an adjusted OR of 1.70 (95% CI 1.37–2.10, p < 0.001). For hospital admission, the unadjusted OR for an increase of one in CCI was 1.15 (95% CI 1.01–1.30, p = 0.035) and the adjusted OR was 1.11 (95% CI 0.95–1.30, p = 0.189). The unadjusted OR for 90-day ED revisits was 1.15 (95% CI 1.03–1.29, p = 0.016), whereas the adjusted OR was 1.03 (95% CI 0.90–1.18, p = 0.636).
Table 2 illustrates the associations between dichotomous study variables, confounding factors and study outcomes.
Recurrent ED visits – Spearman rank correlative analysis. Among the patients who revisited the ED within 90 days (n = 165), there was a very weak positive correlation between the number of regular medications and the number of 90-day ED revisits (ρ = 0.16, n = 165, p = 0.042). Additionally, a weak positive correlation was observed between the number of PIMs and the number of 90-day ED revisits (ρ = 0.28, n = 165, p < 0.001). Repeating the correlative analysis in the whole patient population showed similar results regarding the number of regular medications (ρ = 0.19, n = 391, p < 0.001) and the number of PIMs (ρ = 0.10, n = 386, p = 0.043) on the number of 90-day ED revisits.
Table 2
Unadjusted and adjusted odds ratios of dichotomous medication-related variables and confounding factors for predicting study outcomes.
Outcome / variable | N (%) / median (IQR) | OR | 95% CI | p-value |
90-day mortality (N = 32) |
Polypharmacy* | 22 (69) | 0.50 | 0.23–1.11 | 0.090 |
Adjusted | 0.17 | 0.06–0.45 | < 0.001 |
Excessive polypharmacy* | 11 (34) | 0.70 | 0.28–1.73 | 0.433 |
Adjusted | 0.21 | 0.06–0.70 | 0.011 |
Use of at least one PIM | 13 (41) | 1.11 | 0.53–2.34 | 0.785 |
Adjusted | 0.88 | 0.38–2.04 | 0.768 |
CCI Adjusted | 7 (5–10) | 1.60 1.70 | 1.33–1.91 1.37–2.10 | < 0.001 < 0.001 |
Female sex | 18 (56) 81 (76–89) 48 (30–78) | 0.62 | 0.30–1.29 | 0.199 |
Age | 0.96 | 0.91–1.01 | 0.146 |
eGFR | 0.98 | 0.96-1.00 | 0.046 |
Hospital admission (N = 269) |
Polypharmacy* Adjusted | 222 (83) | 1.52 1.18 | 0.91–2.56 0.66–2.13 | 0.111 0.573 |
Excessive polypharmacy* Adjusted | 89 (33) | 2.03 1.30 | 1.09–3.79 0.58–2.88 | 0.026 0.526 |
Use of at least one PIM Adjusted | 101 (38) | 0.80 0.72 | 0.52–1.24 0.45–1.14 | 0.319 0.158 |
CCI Adjusted | 6 (5–7) | 1.15 1.11 | 1.01–1.30 0.95–1.30 | 0.035 0.189 |
Female sex Age eGFR | 94 (35) 83 (78–89) 61 (42–79) | 0.80 0.98 1.00 | 0.51–1.27 0.95–1.01 0.99–1.01 | 0.344 0.265 0.991 |
90-day ED revisit (N = 165) |
Polypharmacy* | 141 (86) | 1.79 | 1.05–3.04 | 0.032 |
Adjusted | | 1.58 | 0.88–2.84 | 0.124 |
Excessive polypharmacy* | 58 (35) | 2.17 | 1.19–3.97 | 0.012 |
Adjusted | | 2.35 | 1.12–4.93 | 0.024 |
Use of at least one PIM | 70 (42) | 1.27 | 0.84–1.92 | 0.256 |
Adjusted | | 1.36 | 0.88–2.10 | 0.165 |
CCI Adjusted | 6 (5–7) | 1.15 1.03 | 1.03–1.29 0.90–1.18 | 0.016 0.636 |
Female sex Age eGFR | 62 (38) 85 (79–90) 58 (41–78) | 0.73 1.03 0.99 | 0.48–1.11 1.00-1.06 0.99-1.00 | 0.137 0.079 0.240 |
*Patients with < 5 regular medications as a reference group
IQR = interquartile range, OR = odds ratio, CI = confidence interval, PIM = potentially inappropriate medication, eGFR = estimated glomerular filtration rate, ED = emergency department